Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study

被引：0
|
作者：
Yu, X. [1 ]
Shen, L. [2 ]
Hao, J. [3 ]
Wang, L. [4 ]
Pan, H. [5 ]
Han, G. [6 ]
Xu, J. [7 ]
Zhang, Y. [8 ]
Yang, S. [9 ]
Ying, J. [10 ]
Li, M. [11 ]
Begic, D. [12 ]
Lu, B. [12 ]
Xu, R. [13 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200433, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing Canc Hosp, Oncol, Beijing 100871, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Oncol, Tianjin, Peoples R China
[4] 1st Shanghai Peoples Hosp, Oncol, Shanghai, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Oncol, Hangzhou 310003, Zhejiang, Peoples R China
[6] 4th Mil Med Univ, Xijing Hosp, Oncol, Xian, Peoples R China
[7] 307th Hosp PLA AMMS China, Oncol, Beijing, Peoples R China
[8] 1st Hosp Harbin Inst Hematol, Oncol, Harbin, Peoples R China
[9] Henan Prov Anticanc Hosp, Oncol, Zhengzhou, Peoples R China
[10] Zhejiang Canc Hosp, Oncol, Hangzhou, Zhejiang, Peoples R China
[11] Celgene, Biostat, Summit, NJ USA
[12] Celgene, CR&D, Summit, NJ USA
[13] Sun Yat Sen Univ, Affiliated Hosp 1, Oncol, Guangzhou 510275, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
223P
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [31] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Goldstein, David
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian D.
    Biankin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [32] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Filipazzi, V.
    Dalu, D.
    Isabella, L.
    Tosca, N.
    Ferrario, S.
    Gambaro, A.
    Somma, L.
    Fasola, C.
    Pellegrini, I.
    Bombonati, G.
    Curcio, R.
    Damiani, E.
    Cattaneo, M. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [34] Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian D.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P plus GEM) for unresectable locally advanced pancreatic cancer (LAPC)
    Tanimoto, A.
    Yagisawa, M.
    Nakano, S.
    Kawamoto, Y.
    Yuki, S.
    Ishiguro, A.
    Takahata, T.
    Sato, A.
    Iwanaga, I.
    Ehira, N.
    Uebayashi, M.
    Muto, O.
    Sasaki, T.
    Hatanaka, K.
    Tateyama, M.
    Wakabayashi, T.
    Dazai, M.
    Minami, S.
    Sakata, Y.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Updated analysis of weekly nab-Paclitaxel (P) plus Gemcitabine (G) with metastatic pancreatic cancer (MPC): Phase I/II trial
    Omuro, Yasushi
    Ueno, Hideki
    Ikeda, Masafumi
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2015, 26 : 88 - 89
  • [37] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [38] Tumor burden reduction between primary and metastatic sites in advanced pancreatic cancer patients (pts) undergoing chemotherapy with nab-paclitaxel (Nab-P) and gemcitabine (Gem)
    Ventriglia, J.
    Laterza, M. M.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Diana, A.
    Troiani, T.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [39] A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
    Hidalgo, Manuel
    Garcia-Carbonero, Rocio
    Lim, Kian-Huat
    Messersmith, Wells A.
    Garrido-Laguna, Ignacio
    Borazanci, Erkut
    Lowy, Andrew M.
    Rodriguez, Laura Medina
    Laheru, Daniel
    Salvador-Barbero, Beatriz
    Malumbres, Marcos
    Shields, David J.
    Grossman, Joseph E.
    Huang, Xin
    Tammaro, Meggan
    Martini, Jean-Francois
    Yu, Yanke
    Kern, Kenneth
    Macarulla, Teresa
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (11): : 1326 - 1333
  • [40] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345